Drug Profile
Troriluzole - Biohaven Pharmaceuticals
Alternative Names: BHV-4157; BHV-4157a; Dazluma; FC 4157; trigriluzole; Trigriluzole-Biohaven Pharmaceuticals; Troriluzole-hydrochlorideLatest Information Update: 21 Nov 2023
Price :
$50
*
At a glance
- Originator Yale University
- Developer Biohaven Pharmaceutical Holding Company; Biohaven Pharmaceuticals; Global Coalition for Adaptive Research; National Cancer Institute (USA); Rutgers Cancer Institute of New Jersey
- Class Acetamides; Amines; Antidementias; Antineoplastics; Anxiolytics; Behavioural disorder therapies; Benzothiazoles; Fluorinated hydrocarbons; Neuroprotectants; Peptides; Small molecules
- Mechanism of Action Excitatory amino acid antagonists; Glutamate release inhibitors; Voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Spinocerebellar degeneration
- Phase III Obsessive-compulsive disorders
- Phase II/III Alzheimer's disease; Glioblastoma
- Phase II Malignant melanoma
- No development reported Lymphoma; Solid tumours
- Discontinued Anxiety disorders
Most Recent Events
- 14 Nov 2023 Preregistration for Spinocerebellar degeneration in European Union (PO)
- 14 Nov 2023 EMA validates the Marketing Authorization Application (MAA) for troriluzole for Spinocerebellar degeneration
- 13 Sep 2023 Biohaven initiates an expanded access program to provide troriuzole for treatment of Spinocerebellar degeneration (PO) in September 2023 (NCT06034886)